首页> 外文期刊>Cell death & disease. >Sensitizing tumor cells to conventional drugs: HSP70 chaperone inhibitors, their selection and application in cancer models
【24h】

Sensitizing tumor cells to conventional drugs: HSP70 chaperone inhibitors, their selection and application in cancer models

机译:将肿瘤细胞敏化至常规药物:HSP70伴侣抑制剂,其在癌症模型中的选择和应用

获取原文
           

摘要

Hsp70 chaperone controls proteostasis and anti-stress responses in rapidly renewing cancer cells, making it an important target for therapeutic compounds. To date several Hsp70 inhibitors are presented with remarkable anticancer activity, however their clinical application is limited by the high toxicity towards normal cells. This study aimed to develop assays to search for the substances that reduce the chaperone activity of Hsp70 and diminish its protective function in cancer cells. On our mind the resulting compounds alone should be safe and function in combination with drugs widely employed in oncology. We constructed systems for the analysis of substrate-binding and refolding activity of Hsp70 and to validate the assays screened the substances representing most diverse groups of chemicals of InterBioScreen library. One of the inhibitors was AEAC, an N-amino-ethylamino derivative of colchicine, which toxicity was two-orders lower than that of parent compound. In contrast to colchicine, AEAC inhibited substrate-binding and refolding functions of Hsp70 chaperones. The results of a drug affinity responsive target stability assay, microscale thermophoresis and molecular docking show that AEAC binds Hsp70 with nanomolar affinity. AEAC was found to penetrate C6 rat glioblastoma and B16 mouse melanoma cells and reduce there the function of the Hsp70-mediated refolding system. Although the cytotoxic and growth inhibitory activities of AEAC were minimal, the compound was shown to increase the antitumor efficiency of doxorubicin in tumor cells of both types. When the tumors were grown in animals, AEAC administration in combination with doxorubicin exerted maximal therapeutic effect prolonging animal survival by 10–15 days and reducing tumor growth rate by 60%. To our knowledge, this is the first time that this approach to the high-throughput analysis of chaperone inhibitors has been applied, and it can be useful in the search for drug combinations that are effective in the treatment of highly resistant tumors.
机译:HSP70伴侣控制蛋白质抑制和抗应力反应在快速更新的癌细胞中,使其成为治疗化合物的重要靶标。迄今为止,几种HSP70抑制剂具有显着的抗癌活性,然而,它们的临床应用受到正常细胞的高毒性的限制。本研究旨在开发测定以搜索降低HSP70伴侣活性的物质,并在癌细胞中减少其保护功能。在我们的思想中,仅由所得化合物应该是安全的,并且与肿瘤中广泛使用的药物组合使用。我们构建了用于分析HSP70的底物结合和重折叠活性的系统,并验证测定筛选的物质,该物质代表杂交文库的肾间化学品组化学品组。其中一种抑制剂是AEAC,血清晶的N-氨基乙基氨基衍生物,毒性比母体化合物低两次。与Colchicine相比,AEAC抑制了Hsp70伴侣的基质结合和重折叠功能。药物亲和力响应靶稳定性测定,微观硫贫旧型和分子对接的结果表明,AEAC与纳米摩尔亲和力结合HSP70。发现AEAC渗透C6大鼠胶质母细胞瘤和B16小鼠黑素瘤细胞,并减少HSP70介导的重折叠系统的功能。虽然AEAC的细胞毒性和生长抑制活性最小,但显示该化合物以增加两种类型的肿瘤细胞中的多柔比星的抗肿瘤效率。当肿瘤生长动物时,AEAC给药与多柔比星组合施加最大治疗效果延长动物存活率10-15天,并将肿瘤生长速率降低60%。为了我们的知识,这是第一次应用了这种方法对伴侣抑制剂的高通量分析,并且可以在寻找有效治疗高度抗性肿瘤的药物组合中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号